Primary Breast Lymphoma: A Rare Clinical Entity.

World J Oncol

Department of Surgery, Meharry Medical College, School of Medicine, USA.

Published: June 2011

Localized primary breast lymphoma is very rare. The typical clinical and radiographic presentation of isolated primary breast lymphoma mimics that of breast adenocarcinoma. Histologic diagnosis of primary breast lymphoma relies heavily on Hematoxylin and Eosin pathologic evaluation and immunohistochemical staining. Cytotoxic systemic chemotherapy is the primary treatment for this disease with the occasional need for adjuvant radiation therapy or surgical resection. This case report outlines the diagnosis and management of a patient with primary breast lymphoma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649669PMC
http://dx.doi.org/10.4021/wjon319wDOI Listing

Publication Analysis

Top Keywords

primary breast
20
breast lymphoma
20
lymphoma rare
8
primary
6
lymphoma
5
breast
5
rare clinical
4
clinical entity
4
entity localized
4
localized primary
4

Similar Publications

Utilizing machine-learning techniques on MRI radiomics to identify primary tumors in brain metastases.

Front Neurol

January 2025

Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Objective: To develop a machine learning-based clinical and/or radiomics model for predicting the primary site of brain metastases using multiparametric magnetic resonance imaging (MRI).

Materials And Methods: A total of 202 patients (87 males, 115 females) with 439 brain metastases were retrospectively included, divided into training sets (brain metastases of lung cancer [BMLC]  = 194, brain metastases of breast cancer [BMBC]  = 108, brain metastases of gastrointestinal tumor [BMGiT]  = 48) and test sets (BMLC  = 50, BMBC  = 27, BMGiT  = 12). A total of 3,404 quantitative image features were obtained through semi-automatic segmentation from MRI images (T1WI, T2WI, FLAIR, and T1-CE).

View Article and Find Full Text PDF

Background Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a highly aggressive subtype characterized by a high recurrence rate. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, has shown improved outcomes; however, its effectiveness in cases with brain metastases remains unclear. The T-DM1 biosimilar has emerged as a cost-effective treatment option.

View Article and Find Full Text PDF

Introduction: Breast cancer is the most common cancer in females. Surgery is the gold standard therapy, with modified radical mastectomy (MRM) being the most commonly performed procedure for breast cancer. Management of postoperative pain after MRM poses a clinical challenge and hence receives utmost priority.

View Article and Find Full Text PDF

Primary apocrine adenocarcinoma, a rare malignancy, is an aggressive tumor rarely reported. It has diagnostic and treatment challenges as it is difficult to distinguish it from metastases due to breast carcinoma. Currently, no data are available for the use of next-generation sequencing to identify the possibility of targeted therapies for metastatic disease.

View Article and Find Full Text PDF

Clinical significance of lipid pathway-targeted therapy in breast cancer.

Front Pharmacol

January 2025

Department of Breast Surgery and Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Globally, breast cancer represents the most common cancer and the primary cause of death by cancer in women. Lipids are crucial in human physiology, serving as vital energy reserves, structural elements of biological membranes, and essential signaling molecules. The metabolic reprogramming of lipid pathways has emerged as a critical factor in breast cancer progression, drug resistance, and patient prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!